Skip to content
Mainboard BSE,NSE Bidding closed

Sai Life Sciences IPO Subscription Status

Sai Life Sciences IPO received bids for 39,85,59,636 shares against 3,88,29,848 offered, an overall subscription of 10.26x at the close of bidding (13 Dec 2024). QIBs lead at 30.93x.

Last updated · day 3 figures

Retail
1.37x
NII
4.92x
QIB
30.93x
Total
10.26x

Where the demand is

Sai Life Sciences IPO subscription by category Each line starts at 1x (fully subscribed) and ends at the category's subscription multiple, on a logarithmic scale. Values are listed in the table below. 0.1x 1x 10x 100x QIB QIB: 30.93x 30.93x NII NII: 4.92x 4.92x bNII bNII: 6.00x 6.00x sNII sNII: 2.74x 2.74x Retail Retail: 1.37x 1.37x Total Total: 10.26x 10.26x
Log scale. Lines run from 1x (fully subscribed): right means more demand than shares, left means shares still unbid.

Sai Life Sciences IPO subscription by category

Category Shares offered Shares bid Amount bid Subscription
QIB 1,06,71,763 33,01,25,058 ₹18,123.87 Cr 30.93x
NII 84,47,426 4,15,22,058 ₹2,279.56 Cr 4.92x
bNII above ₹10 lakh 56,31,618 3,38,13,693 ₹1,856.37 Cr 6.00x
sNII ₹2–10 lakh 28,15,808 77,08,365 ₹423.19 Cr 2.74x
Retail 1,97,10,659 2,69,12,520 ₹1,477.50 Cr 1.37x
Total 3,88,29,848 39,85,59,636 ₹21,880.92 Cr 10.26x

* Shares Offered and Total Amount are calculated based on the upper price of the issue price range. * The portion of anchor investors (or market makers) is not included in the total number of shares offered.

Sai Life Sciences IPO subscription day-wise

Category Day 3
QIB 30.93x
NII 4.92x
bNII 6.00x
sNII 2.74x
Retail 1.37x
Total 10.26x
Total added 10.26x

Cumulative figures at the end of each day. Read across a row to see how demand built up. Shading deepens as subscription rises above 1x; "Total added" is how much overall subscription grew that day.

Sai Life Sciences IPO reservation

Category Shares Share of issue
Qualified Institutional Buyers 1,06,71,763 27.48%
Non-Institutional Investors 84,47,426 21.75%
bNII · above ₹10 lakh 56,31,618 67% of NII
sNII · ₹2–10 lakh 28,15,808 33% of NII
Retail Individual Investors 1,97,10,659 50.76%
Public issue 3,88,29,848 100%

Allotment Chances Note

These are estimates from the latest application and subscription figures. Actual chances are usually somewhat better, because:

  • Not every bid is at the cut-off price. Bids below the final issue price are rejected before the lottery, so fewer applications compete.
  • Multiple-lot applications count once. In an oversubscribed retail or sNII portion, each application gets at most one minimum lot in the draw, however many lots it bid for.
  • Invalid applications drop out. Unapproved UPI mandates, PAN mismatches and duplicate applications are removed before allotment.

Applying for more lots in the retail category does not improve your odds; applying from separate family accounts does.

Sai Life Sciences IPO subscription: FAQs

What is the overall subscription of Sai Life Sciences IPO?
Sai Life Sciences IPO is subscribed 10.26x overall as of day 3 (13 December 2024), with bids for 39,85,59,636 shares against 3,88,29,848 offered.
What is the retail subscription of Sai Life Sciences IPO?
The retail portion is subscribed 1.37x as of day 3 (13 December 2024).
What is the QIB and NII subscription of Sai Life Sciences IPO?
QIBs have subscribed 30.93x of their portion, and NIIs 4.92x (bNII 6.00x, sNII 2.74x) as of day 3 (13 December 2024).
How can I check Sai Life Sciences IPO subscription status live?
This page shows category-wise and day-wise figures and is updated during bidding hours. The same data is published on the BSE and NSE websites under the issue name.
How do I apply for Sai Life Sciences IPO?
Apply online through your broker or bank using UPI or ASBA. Choose the IPO, enter the number of lots and bid price (retail investors can bid at the cut-off price), and approve the UPI mandate before the issue closes on 13 December 2024.

Subscription figures are compiled from BSE and NSE bid data and can be revised by the exchanges after the issue closes. For information only; not investment advice.